Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols

Protocols

EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.

Contents

Title Abstract Investigator
SELDI Profiling of serum and urine from patients with urologic disease in support of bladder cancer studies Semmes, John
SELDI Validation Study Phase II This project –A Comprehensive Program for the Validation of Prostate Cancer Early Detection with Novel Protein Identification Techniques -- is divided into ... Semmes, John
SELDI and LC-MS/MS discovery and profiling study of hepatocarcinomas Semmes, John
SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BACKGROUND: This study aimed to show that SHOX2 DNA methylation is a tumor marker in patients with suspected lung cancer by using bronchial fluid aspirated ... Schmidt, Bernd
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study Phase II specimens from 160 ovarian cancer cases and 640 benign disease or general population controls were assembled from four Early Detection Research ... Cramer, Daniel
San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR) To determine if there are ways to predict which men will get prostate cancer, if there are ways to predict how a prostate cancer will develop (for example, ... Thompson, Ian M.
Screen Detection of Mismatch Repair Deficient Colorectal Neoplasias Using a Stool Based DNA Analysis Lynch, Henry
Seattle Area Hormone and Reproductive Epidemiology Breast Cancer Study The SHARE Study (Seattle Area Hormone And Reproductive Epidemiology Breast Cancer Study) is a five-year, population-based case-control study, funded by the ... Li, Christopher
Soluble Mesothelin Related Peptide (SMRP) and Osteopontin (OPN) as Early Detection Markers for Malignant Mesothelioma (MM) Phase I: - Identification and assemblage of representative cohorts of individuals with MM, no malignancies but increased risk for MM due to asbestos exposure, ... Pass, Harvey Ira
Spectral Markers for Early Detection of Colon Neoplasia Not listed
Standard Specimen Reference Set: Breast The primary objective of this study is to assemble a well-characterized set of blood specimens to test biomarkers that, in conjunction with mammography, can ... Marks, Jeffrey
Standard Specimen Reference Set: Liver Utilize the remaining specimens collected under the DCP protocol to develop and validate markers for the early detection of HCC Volk, Michael L.
Standard Specimen Reference Set: Lung The NCI/EDRN/SPORE Lung Cancer Biomarkers Group (LCBG) began its activities back in November 2004 and developed clear objectives and strategies on how to begin ... Bigbee, William L.
Standard Specimen Reference Set: Pancreatic The primary objective of the EDRN Pancreatic Cancer Working Group Proposal is to create a reference set consisting of well-characterized serum/plasma specimens ... Brand, Randall E.
Standard Specimen Reference Set: Prostate To collect biologic samples on men prior to prostate biopsy, in association with clinical information and common data elements appropriate for evaluation of ... Sanda, Martin
Standard Specimen Reference Set: Colon The Early Detection Research Network, Great Lakes-New England Clinical, Epidemiological and Validation Center (GLNE CVC) announces the availability of serum, ... Brenner, Dean
Study 5: Phase 2 and 3 Validations of Putative Breast Cancer Early Detection Candidates Li, Christopher
T2-Erg Team Project Prostate cancer (PCa) is the third leading cause of cancer-related deaths among United States men, accounting for 33% of such diagnosed cancers.(1) An ... Sanda, Martin
Tamoxifen and Second Breast Cancer: Epidemiology/Pathology The BRITE Study (Breast Cancer Research Investigation of Treatment Effects) is a five-year, population-based nested case-control study, funded by the National ... Li, Christopher
Targeted Sequencing for Discovery and Validation of DNA Methylation Markers of Colon Cancer Metastasis Colon cancer is the second leading cause of cancer death in the United States. A key issue in treating colon cancer patients is inability to accurately predict ... Markowitz, Sanford
The Biomarker Knowledge System Informatics Pilot Project Supplement To The Biomarker Development Laboratory at Moffitt (Bedlam) The Biomarker Knowledge System Informatics Pilot Project goal will develop network interfaces among databases that contain information about existing clinical ... Tockman, Melvyn S.
The Early Detection Research Network: Biomarker Reference Laboratories Chia, David
The Prostate Tumor Microenvironment Exhibits differentially expressed Genes Useful for Diagnosis To develop a multi-site prospective clinical validation trial of the multigene diagnostic signature for the diagnosis of prostate cancer from non tumor ... Mercola, Dan
Triple Negative Breast Cancer Team Project Early diagnosis of triple negative breast cancer would likely have significant impact on overall breast cancer mortality. This proposal is designed to ... Anderson, Karen
US-Turkey Cappadocia Mesothelioma Project Study never launched. Pass, Harvey Ira
Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer BACKGROUND: Lung cancer is the leading cause of cancer deaths worldwide. New diagnostics are needed to detect early stage lung cancer because it may be cured ... Ostroff, Rachel
Upgrading Reference Set Thompson, Ian M.
Use of Exogenous Progestins and Risk of In Situ and Invasive Breast Cancer The SHARE II Study (Seattle Area Hormone And Reproductive Epidemiology Breast Cancer Study) is a 6 year grant funded by the Breast Cancer Research Program of ... Li, Christopher
Using MALDI-IMS and MRM to stablish a pipeline for discovery and validation of tumor neovasculature biomarker candidates. In an effort to circumvent the limitations associated with biomarker discovery workflows involving cell lines and cell cultures, histology-directed MALDI ... Gambhir, Sanjiv
Utility of Biomarkers for Early Detection of Malignant Mesothelioma in a High-risk Population Pass, Harvey Ira
Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.